Jupiter Neurosciences, Inc.JUNS

Jupiter Neurosciences Inc. markets JOTROL™ as a first-of-its-kind resveratrol therapy that reaches therapeutic blood levels without gut irritation, positioning the pill as a multi-indication anti-inflammatory and antioxidant. The homepage hails “treatment possibilities in many indications,” and the company points to JOTROL™’s purported mechanisms-anti-inflammatory, oxidative-stress-reducing, and other action pathways-as the basis for a pipeline of neurological applications. What the marketing site does not show is a revenue line that tops $18k for the quarter ended 31 March 2026, or any product on the market generating meaningful sales.

Jupiter’s latest 10-Q (31 March 2026) tells the real story: revenue of $18,652 sits against net losses of $2.1 million, operating losses of $2.0 million, and negative shareholders’ equity of $2.8 million. Cash used in operating activities was $1.4 million. Inventories of $148,068 shrank by $11,722 during the quarter, hardly the kind of build-up you’d expect from a product storming the market. Research and development spend was $411,049, which is less than half a million dollars, and that outlay produced no revenue to offset it.

The 10-Q also shows current assets of $3.9 million against current liabilities of $6.7 million, leaving a working-capital deficit that would embarrass a late-stage clinical outfit, let alone one still pre-clinical. Diluted earnings per share were minus $0.06 on 35.3 million diluted shares. The balance-sheet arithmetic is unambiguous: Jupiter is a cash-burning research vehicle with no commercial revenues and thin disclosure on milestones or timelines.

On the product front, Jupiter’s pipeline page lists a development strategy table across multiple CNS targets, but the image itself carries no timelines, endpoints, or probabilities. The site repeats the resveratrol claim and showcases an animated banner of blue waves, a visual that says nothing about regulatory status or clinical progress. These pages read like pre-regulatory brochures rather than post-approval marketing collateral.

SEC filings reveal that Jupiter and PharmAla have a side letter that could deliver up to $20 million upon FDA approval of an NDA for a “Licensed Product,” payable in cash or Jupiter shares at PharmAla’s election. The agreement is couched in the dry language of milestone payments, but it underscores how far Jupiter is from self-funded commercialisation. The 8-K filed 30 June 2026 further notes that Jupiter’s therapies target neuroinflammation and CNS disorders, which is consistent with the company’s public positioning but provides no revenue, regulatory progress, or near-term cash-flow visibility.

Ownership disclosures show a shifting register of insider stakes, but none of the filings discussed here quantify insider buying or selling volumes, nor do they outline any material change in beneficial ownership that would materially alter the control structure. The SEC’s ownership XML files for 22 July 2026 list positions without narrative context or commentary, leaving outsiders to infer rather than to know.

For chart context, Jupiter trades on a thinly liquid market; investors seeking price history will find no robust candlestick archive on major platforms. The absence of a clean, continuous chart is itself a data point: thin float, low volume, and limited market-making interest. No source in the evidence pack supplies a TradingView route, so any attempt to overlay moving averages or support lines would be speculation rather than sourcing.